Danaher merging Cytiva and Pall to create $7.5bn bioprocess juggernaut
Combining Cytiva and Pall will create the “broadest†and “deepest†bioprocess product portfolio in the industry, says Danaher Corporation. The decision to create ‘The Biotechnology Group’ by merging Danaher’s two bioprocess businesses was announced at the firm’s 2022 Investor & ...
Terumo Blood and Cell Technologies (BCT) has launched the Quantum Flex Cell Expansion System, saying healthier cells and scalability are among th ...- Valneva has ended its manufacturing partnership with IDT Biologika following a reduction in demand for its COVID-19 vaccine VLA2001 from the Euro ...
- A US FDA Form 483 has revealed visible foreign particles in certain batches of drug product at Catalent’s Bloomington, Indiana facility.
Th ...
- MeiraGTx has opened what it claims is the first commercial-scale gene therapy manufacturing site in Shannon, Ireland.
Clinical stage gene the ...
Recent Tweets
-
Not long till BioProcess Insider head to Boston for #BWB
2 days ago
-
T-cell receptor firm TCR² Therapeutics told delegates at #AdvancedTherapiesEurope it is key to embed culture into y… https://t.co/82qHSW5Ne4
3 weeks ago
-
RT @BioProInsider: Stuart Curbishley: ‘Most drug discoveries tend to happen inside global pharmaceutical companies but in the CGT spac… https://t.co/PvbKZ7lD3t
3 weeks ago
-
And that’s a wrap! Keep your eyes peeled for articles about the event on BioProcess Insider #AdvancedTherapiesEurope
3 weeks ago
